Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02404220 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02404220 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 30 participants.
The verdict
NCT02404220, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL). This is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.
Interventions
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Entospletinib
- DRUG CNS Prophylaxis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-05-06 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02404220
The ClinicalTrials.gov registry entry for NCT02404220 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT02404220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02404220 about?
NCT02404220 is a clinical study titled "Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)". The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL). This is a dose escalation study in which after 2 ...
What is the current status of trial NCT02404220?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-05-06. Estimated completion is 2018-12-17.
What interventions are being tested in trial NCT02404220?
The interventions under investigation include: Dexamethasone (DRUG), Vincristine (DRUG), Entospletinib (DRUG), CNS Prophylaxis (DRUG).
Who is sponsoring clinical trial NCT02404220?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.